Can Immunotherapy Be Effective in Certain NETs Patients?

November 13, 2018
Dave Levitan
Dave Levitan

In general, NETs are considered an “immunological desert,” but a new study showed some promise for immunotherapy.

The anti–programmed death 1 (PD-1) agent spartalizumab showed promising clinical activity in patients with well-differentiated nonfunctional neuroendocrine tumors (NETs), according to results of a phase II trial.

Spartalizumab is an anti–PD-1 antibody with activity against both PD-1 ligands, PD-L1 and PD-L2. The new study included a cohort of 95 patients with well-differentiated NETs (30 with thoracic NETs, 33 with pancreatic NETs, and 32 with gastrointestinal NETs), as well as 21 patients with poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). The results of the study were presented by James C. Yao, MD, of the University of Texas MD Anderson Cancer Center, at the European Society for Medical Oncology (ESMO) 2018 Congress.

Patients with well-differentiated advanced NETs were eligible if they had progressed on prior therapy, including everolimus, while the GEP-NEC patients were eligible if they had progressed on one line of chemotherapy. All patients in the trial received spartalizumab via a 30-minute infusion once every 4 weeks until disease progression or unacceptable toxicity.

In the full well-differentiated cohort, there were 7 partial responses (7%), and 55% had stable disease, while 31% had progressive disease. The confirmed objective response rate was 7%, and the disease control rate was 63%. In the GEP-NEC cohort, the objective response rate was 5%, and the disease control rate was 19%.

The thoracic NETs patients fared best with spartalizumab, with limited responses seen in the pancreatic and GI NETs groups; responses seemed to be associated with PD-L1 expression. In the thoracic NETs cohort, two of five PD-L1–positive patients had a partial response. PD-L1 positivity was more common in the GEP-NEC cohort; among 14 PD-L1–positive patients in that group, the partial response rate was 43%.

The most common adverse events regardless of cause included abdominal and back pain, anemia, dyspnea, and hypertension.

Kjell Öberg, MD, PhD, of Uppsala University in Sweden, discussed the study for ESMO. “We have hope,” he said. “We see that maybe there are some tumor types that might respond to immunotherapy.” In general, NETs are considered an “immunological desert.” There is usually very low infiltration of immune cells in these tumors, and there are a low number of genetic mutation events.

Öberg noted that in the new study, the partial responses were seen only in those tumors with CD8+ cell infiltration. He noted, though, that conversion of NETs to an “inflammatory state” can be achieved through various means, including oncolytic viruses or peptide receptor radionuclide therapy.